Maze Therapeutics, Inc.’s Quiet Period Will End Tomorrow (NASDAQ:MAZE)

Posted by Renee Jackson on Mar 11th, 2025

Maze Therapeutics’ (NASDAQ:MAZE – Get Free Report) quiet period will end on Wednesday, March 12th. Maze Therapeutics had issued 8,750,000 shares in its IPO on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. During Maze Therapeutics’ quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Leerink Partners assumed coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They set an “outperform” rating and a $28.00 price target for the company. Leerink Partnrs upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 25th. Guggenheim initiated coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued a “buy” rating and a $19.00 price target for the company. Finally, JPMorgan Chase & Co. started coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued an “overweight” rating and a $30.00 price target for the company. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Maze Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $25.67.

Read Our Latest Stock Report on MAZE

Maze Therapeutics Stock Down 1.8 %

Shares of NASDAQ:MAZE opened at $11.78 on Tuesday. Maze Therapeutics has a 1 year low of $10.08 and a 1 year high of $17.00.

Maze Therapeutics Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.